BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18931839)

  • 1. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study.
    Chatterton BE; Ho Shon I; Baldey A; Lenzo N; Patrikeos A; Kelley B; Wong D; Ramshaw JE; Scott AM
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):354-61. PubMed ID: 18931839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
    Katsoulis IE; Wong WL; Mattheou AK; Damani N; Chambers J; Livingstone JI
    Int J Surg; 2007 Dec; 5(6):399-403. PubMed ID: 17631431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
    Barber TW; Duong CP; Leong T; Bressel M; Drummond EG; Hicks RJ
    J Nucl Med; 2012 Jun; 53(6):864-71. PubMed ID: 22582047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma.
    Salahudeen HM; Balan A; Naik K; Mirsadraee S; Scarsbrook AF
    Clin Radiol; 2008 Jul; 63(7):765-73. PubMed ID: 18555034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
    Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of FDG-PET for staging of oesophageal cancer.
    Imdahl A; Hentschel M; Kleimaier M; Hopt UT; Brink I
    Langenbecks Arch Surg; 2004 Aug; 389(4):283-8. PubMed ID: 15197549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of (18)F-FDG PET/CT on the therapeutic management in the initial staging of the esophageal cancer].
    Pifarré-Montaner P; Fernández-León A; de Juan R; del Ama-Salvador ME; Galán M; Gámez-Cenzano C; Sans M
    Rev Esp Med Nucl; 2009; 28(3):101-5. PubMed ID: 19558949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.
    You JJ; Wong RK; Darling G; Gulenchyn K; Urbain JL; Evans WK
    J Thorac Oncol; 2013 Dec; 8(12):1563-9. PubMed ID: 24389439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study.
    Scott AM; Gunawardana DH; Wong J; Kirkwood I; Hicks RJ; Ho Shon I; Ramshaw JE; Robins P
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):347-53. PubMed ID: 18931840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Has integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer?
    Torrance AD; Almond LM; Fry J; Wadley MS; Lyburn ID
    Surgeon; 2015 Feb; 13(1):19-33. PubMed ID: 24206935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited additional value of positron emission tomography in staging oesophageal cancer.
    van Westreenen HL; Westerterp M; Sloof GW; Groen H; Bossuyt PM; Jager PL; Comans EF; van Dullemen HM; Fockens P; Stoker J; van der Jagt EJ; van Lanschot JJ; Plukker JT
    Br J Surg; 2007 Dec; 94(12):1515-20. PubMed ID: 17902092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer.
    Duong CP; Demitriou H; Weih L; Thompson A; Williams D; Thomas RJ; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):759-69. PubMed ID: 16470369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
    Onal C; Torun N; Guler OC; Yildirim BA
    Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of novel ¹⁸F-FDG PET/CT defined tumour variables in patients with oesophageal cancer.
    Foley KG; Fielding P; Lewis WG; Karran A; Chan D; Blake P; Roberts SA
    Eur J Radiol; 2014 Jul; 83(7):1069-1073. PubMed ID: 24794862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Better assessment of nodal metastases by PET/CT fusion compared to side-by-side PET/CT in oesophageal cancer.
    Schreurs LM; Pultrum BB; Koopmans KP; Verhoef CC; Jager PL; Van Dam GM; Groen H; Van Der Jagt EJ; Plukker JT
    Anticancer Res; 2008; 28(3B):1867-73. PubMed ID: 18630473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbon-11 choline or FDG-PET for staging of oesophageal cancer?
    Jager PL; Que TH; Vaalburg W; Pruim J; Elsinga P; Plukker JT
    Eur J Nucl Med; 2001 Dec; 28(12):1845-9. PubMed ID: 11734925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study.
    Cheze-Le Rest C; Metges JP; Teyton P; Jestin-Le Tallec V; Lozac'h P; Volant A; Visvikis D
    Nucl Med Commun; 2008 Jul; 29(7):628-35. PubMed ID: 18528185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18)F-FDG PET-detected synchronous primary neoplasms in the staging of esophageal cancer: incidence, cost, and impact on management.
    Malik V; Johnston C; Donohoe C; Claxton Z; Lucey J; Ravi N; Reynolds JV
    Clin Nucl Med; 2012 Dec; 37(12):1152-8. PubMed ID: 23154472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of positron emission tomography in the (re-)staging of oesophageal cancer.
    Westerterp M; Van Westreenen HL; Sloof GW; Plukker JT; Van Lanschot JJ
    Scand J Gastroenterol Suppl; 2006; (243):116-22. PubMed ID: 16782630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.